Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 in Advanced Solid Tumors
NCT04324814Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Mar 2020
- Primary completion
- Feb 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of retlirafusp alfa in solid tumor (advanced stage) (7 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Adverse events, Laboratory results and 2 more. Started Mar 2020; status: completed.
02
Drugs
retlirafusp alfa
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04324814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324814.